Recent work by Mo et al. has shown that knockdown of the proteasome subunit, PSMB5, improved bortezomib sensitivity in patients with multiple myeloma through the increased expression of the pro-apoptotic signaling gene, BAX, and decreased expression of the anti-apoptotic genes, BCL2 and AKT [29]. The gene discussed is BCL2; the disease is plasma cell myeloma.